Dr. Reddy's Subsidiary Aurigene Stops Clinical Development of AUR-101 for the Treatment of Psoriasis
Shots:
- Dr. Reddy's subsidiary Aurigene decided to stop the clinical development of AUR-101 in the P-IIb trial (INDUS-3) in patients with mod. to sev. Psoriasis in the US
- The decision was based on the P-IIb trial (INDUS-3) results which showed no desirable benefit to patients & the trial also failed to meet its 1EPs of PASI-75 @12wks. at 200mg, BID and the 400mg, QD while 1EPs was met at 400mg BID dose @12wks. over PBO
- AUR-101 is a potent, oral RORϒt inverse agonist with high selectivity across other ROR isoforms & nuclear hormone receptors. Preclinical toxicology assessments of AUR-101 found it to be safe at several folds of effective human exposures & earlier clinical trials also demonstrated positive pharmacodynamic modulation
Ref: Dr. Reddy | Image: Dr. Reddy
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
